We are pleased to share with you the news that the All Wales Medicines Strategy Group has recommend Telotristat ethyl (Xermelo®) as an option for restricted use in NHS Wales to treat carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
The information the NET Patient Foundation submitted, on behalf of the NET community, helped the All Wales Medicines Strategy Group to understand how this condition affects patients and carers.
The medicine will now become routinely available in the NHS across Wales to treat this condition, according to current Welsh Government policy.
[npfButton size=“small” text=”Find out more” href=”http://www.awmsg.org/awmsgonline/app/appraisalinfo/2037″ background-colour=”#37b8c0″ text-colour=”#ffffff”]